Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs
Abstract The recent discovery of clinically significant data, alongside novel physiological and pathological occurrences surrounding sacubitril/valsartan (Sac/Val) beyond its approved indications, necessitates an urgent reevaluation of its underlying mechanism of action. In the present investigation...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMC
2025-02-01
|
| Seria: | Cardiovascular Diabetology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1186/s12933-025-02627-6 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
